<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Botulinum toxin type A versus anticholinergics for cervical dystonia - Rodrigues, FB - 2021 | Cochrane Library</title> <meta content="Botulinum toxin type A versus anticholinergics for cervical dystonia - Rodrigues, FB - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004312.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Botulinum toxin type A versus anticholinergics for cervical dystonia - Rodrigues, FB - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004312.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004312.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Botulinum toxin type A versus anticholinergics for cervical dystonia" name="citation_title"/> <meta content="Filipe B Rodrigues&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculdade de Medicina da Universidade de Lisboa" name="citation_author_institution"/> <meta content="Gonçalo S Duarte&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculdade de Medicina da Universidade de Lisboa" name="citation_author_institution"/> <meta content="Mafalda Castelão" name="citation_author"/> <meta content="Faculdade de Medicina da Universidade de Lisboa" name="citation_author_institution"/> <meta content="Raquel E Marques" name="citation_author"/> <meta content="Hospital de Santa Maria" name="citation_author_institution"/> <meta content="Joaquim Ferreira" name="citation_author"/> <meta content="Faculdade de Medicina da Universidade de Lisboa" name="citation_author_institution"/> <meta content="Cristina Sampaio" name="citation_author"/> <meta content="CHDI Foundation" name="citation_author_institution"/> <meta content="Austen P Moore" name="citation_author"/> <meta content="The Walton Centre NHS Foundation Trust" name="citation_author_institution"/> <meta content="João Costa" name="citation_author"/> <meta content="Faculdade de Medicina da Universidade de Lisboa" name="citation_author_institution"/> <meta content="jncosta@medicina.ulisboa.pt" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD004312.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004312.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004312.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004312.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Botulinum Toxins, Type A [*therapeutic use]; Muscarinic Antagonists [*therapeutic use]; Neuromuscular Agents [*therapeutic use]; Torticollis [*drug therapy]; Trihexyphenidyl [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004312.pub3&amp;doi=10.1002/14651858.CD004312.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004312\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004312\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","th","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004312.pub3",title:"Botulinum toxin type A versus anticholinergics for cervical dystonia",firstPublishedDate:"Apr 14, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Movement Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004312.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004312.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004312.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004312.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004312.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004312.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004312.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004312.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004312.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004312.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1715 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004312.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0077"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-sec-0071"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/appendices#CD004312-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Botulinum toxin type A versus anticholinergics for cervical dystonia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0004">Filipe B Rodrigues</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0005">Gonçalo S Duarte</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0006">Mafalda Castelão</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0007">Raquel E Marques</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0008">Joaquim Ferreira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0009">Cristina Sampaio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0010">Austen P Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information#CD004312-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>João Costa</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information/en#CD004312-sec-0088">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004312.pub3">https://doi.org/10.1002/14651858.CD004312.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004312-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004312-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004312-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004312-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004312-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD004312-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004312-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004312-abs-0001" lang="en"> <section id="CD004312-sec-0001"> <h3 class="title" id="CD004312-sec-0001">Background</h3> <p>This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition. Before BtA, anticholinergics were the most widely accepted treatment. </p> </section> <section id="CD004312-sec-0002"> <h3 class="title" id="CD004312-sec-0002">Objectives</h3> <p>To compare the efficacy, safety, and tolerability of BtA versus anticholinergic drugs in adults with cervical dystonia. </p> </section> <section id="CD004312-sec-0003"> <h3 class="title" id="CD004312-sec-0003">Search methods</h3> <p>We searched the Cochrane Movement Disorders' Trials Register to June 2003, screened reference lists of articles and conference proceedings to September 2018, and searched CENTRAL, MEDLINE, and Embase, with no language restrictions, to July 2020. </p> </section> <section id="CD004312-sec-0004"> <h3 class="title" id="CD004312-sec-0004">Selection criteria</h3> <p>Double‐blind, parallel, randomised trials (RCTs) of BtA versus anticholinergic drugs in adults with cervical dystonia. </p> </section> <section id="CD004312-sec-0005"> <h3 class="title" id="CD004312-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed records, selected included studies, extracted data using a paper pro forma, and evaluated the risk of bias and quality of the evidence. We resolved disagreements by consensus or by consulting a third review author. If enough data had been available, we were to perform meta‐analyses using a random‐effects model for the comparison of BtA versus anticholinergic drugs to estimate pooled effects and corresponding 95% confidence intervals (95% CI). The primary efficacy outcome was improvement in cervical dystonia‐specific impairment. The primary safety outcome was the proportion of participants with any adverse event. </p> </section> <section id="CD004312-sec-0006"> <h3 class="title" id="CD004312-sec-0006">Main results</h3> <p>We included one RCT of moderate overall risk of bias (as multiple domains were at unclear risk of bias), which included 66 BtA‐naive participants with cervical dystonia. Two doses of BtA (Dysport; week 0 and 8; mean dose 262 to 292 U) were compared with daily trihexyphenidyl (up to 24 mg daily). The trial was sponsored by the BtA producer. </p> <p>BtA reduced cervical dystonia severity by an average of 2.5 points (95% CI 0.68 to 4.32) on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity subscale 12 weeks after injection, compared to trihexyphenidyl. More participants reported adverse events in the trihexyphenidyl treatment group (76 events), compared with the BtA group (31 events); however, the difference in dropouts due to adverse events was inconclusive between groups. There was a decreased risk of dry mouth, and memory problems with BtA, but the differences were inconclusive between groups for the other reported side effects (blurred vision, dizziness, depression, fatigue, pain at injection site, dysphagia, and neck weakness). </p> </section> <section id="CD004312-sec-0007"> <h3 class="title" id="CD004312-sec-0007">Authors' conclusions</h3> <p>We found very low‐certainty evidence that BtA is more effective, better tolerated, and safer than trihexyphenidyl. </p> <p>We found no information on a dose‐response relationship with BtA, differences between BtA formulations or different anticholinergics, the utility of electromyography‐guided injections, or the duration of treatment effect. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004312-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004312-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004312-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004312-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004312-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004312-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD004312-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004312-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004312-abs-0002" lang="en"> <h3>Treatment with botulinum toxin type A or anticholinergic drugs for people with cervical dystonia (involuntary posturing of the head) </h3> <p><b>The review question</b> </p> <p>This is an update of a Cochrane Review. We assessed whether botulinum toxin type A (BtA) was more effective (reduction in severity, disability, and pain) and safer than anticholinergic drugs for people with cervical dystonia (involuntary positioning of the head). </p> <p><b>Background</b> </p> <p>Cervical dystonia, also called spasmodic torticollis, is a disorder that causes undesired, uncontrollable, often painful, abnormal placement of the head. It is a relatively uncommon condition, affecting 57 to 280 people per million. It can be very disabling, and have a negative affect on a person's quality of life. In most cases, the cause is unknown; there is no cure. Since cervical dystonia is normally a long‐term disorder, it requires long‐term treatment. </p> <p>Botulinum toxin type A and anticholinergic drugs are powerful chemical substances that cause a diverse range of responses in the human body. BtA causes severe localised paralysis (an inability to move in the part of the body where it is injected). Anticholinergics, usually taken by mouth, cause more widespread symptoms, and can result in a dry mouth, visual disturbances, bowel and bladder difficulties, increased heart rate, sedation, and confusion or disorientation. Both can be used to treat many conditions, in particular, those with involuntary muscle contractions, such as cervical dystonia. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature to July 2020. We found one study that compared treatment with BtA (Dysport) versus an anticholinergic drug (trihexyphenidyl) for 12 weeks. The study included 66 participants, who had experienced cervical dystonia for an average of 9.4 years, but had never received BtA treatment. On average, they had moderate impairment. The average age of people in the study was 50.7 years. The trial was funded by the BtA drug manufacturer. </p> <p><b>Key results</b> </p> <p>The results show that Dysport, when compared with trihexyphenidyl, may improve symptoms of cervical dystonia, pain, and quality of life. The risk of having an unpleasant or undesirable event, particularly dry mouth and memory issues, was increased in people taking trihexyphenidyl. </p> <p>We found no information on the effects of different doses of BtA, different formulas of BtA or types of anticholinergics, the usefulness of guiding injections by electromyography, or how long the effects lasted. </p> <p><b>Certainty in the evidence</b> </p> <p>Due to limitations in the study methods and size of the study, we have very little confidence in the results. </p> <p>These conclusions may not apply to all people with cervical dystonia. They do not apply to long‐term use of either treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004312-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004312-sec-0077"></div> <h3 class="title" id="CD004312-sec-0078">Implications for practice</h3> <section id="CD004312-sec-0078"> <p>Based on very low‐quality evidence, we are uncertain how the effects of botulinum toxin type A (BtA) compare with trihexyphenidyl. </p> <p>We found very low‐certainty evidence that BtA is more effective, better tolerated, and safer than trihexyphenidyl. People treated with BtA experienced improved disability, pain, and quality of life compared with people treated with trihexyphenidyl. Adverse events were less frequent with BtA. </p> <p>We cannot draw conclusions about other anticholinergic drugs, drug‐dose response, or benefits associated with the use of EMG‐guided injections. We cannot draw conclusions about people who are not BtA‐naive, or people who have other forms of dystonia, as the trial excluded them. </p> </section> <h3 class="title" id="CD004312-sec-0079">Implications for research</h3> <section id="CD004312-sec-0079"> <p>The efficacy and tolerability of BtA in cervical dystonia is well established (<a href="./references#CD004312-bbs2-0012" title="CastelãoM , MarquesRE , DuarteGS , RodriguesFB , FerreiraJ , SampaioC , et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub3] [CD003633]">Castelão 2017</a>; <a href="./references#CD004312-bbs2-0019" title="DuarteGS , CastelãoM , RodriguesFB , MarquesRE , FerreiraJ , SampaioC , et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD004314. [DOI: 10.1002/14651858.CD004314.pub3]">Duarte 2016</a>; <a href="./references#CD004312-bbs2-0051" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD004315. [DOI: 10.1002/14651858.CD004315.pub3] [PMID: 27176573]">Marques 2016</a>), making it difficult to determine which and how many resources should be invested in future research. The magnitude of benefit, as with other movement disorders, varies in a real‐world setting (<a href="./references#CD004312-bbs2-0020" title="DuarteGD , RodriguesFB , FerreiraJJ , CostaJ . Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?Parkinsonism &amp; Related Disorders2018;56:16-9. [DOI: 10.1016/j.parkreldis.2018.06.017]">Duarte 2018</a>; <a href="./references#CD004312-bbs2-0059" title="RodriguesFB , DuarteGS , PrescottD , FerreiraJ , CostaJ . Deep brain stimulation for dystonia. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD012405. [DOI: 10.1002/14651858.CD012405.pub2]">Rodrigues 2019</a>). </p> <p><a href="./references#CD004312-bbs2-0012" title="CastelãoM , MarquesRE , DuarteGS , RodriguesFB , FerreiraJ , SampaioC , et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub3] [CD003633]">Castelão 2017</a><a href="./references#CD004312-bbs2-0019" title="DuarteGS , CastelãoM , RodriguesFB , MarquesRE , FerreiraJ , SampaioC , et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD004314. [DOI: 10.1002/14651858.CD004314.pub3]">Duarte 2016</a><a href="./references#CD004312-bbs2-0051" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD004315. [DOI: 10.1002/14651858.CD004315.pub3] [PMID: 27176573]">Marques 2016</a> </p> <p>We only had access to published research data from one trial of BtA versus anticholinergic drugs in adults with cervical dystonia. The role of anticholinergic drugs in people who do not get benefit with BtA should be further explored, and further studies are needed to establish the relative effectiveness of different anticholinergic drugs, assessing efficacy, safety, duration of effect, and quality of life across regimes. </p> <p>Future research on cervical dystonia should endeavour to establish clinical effectiveness, based on both changes from baseline, and validated measures of minimal clinically important difference or change (<a href="./references#CD004312-bbs2-0009" title="BrożekJL , GuyattGH , SchünemannHJ . How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health and Quality of Life Outcomes2006;4:69.">Brożek 2006</a>). </p> <p>It is still uncertain whether the clinical effectiveness of botulinum toxin or anticholinergic drugs decays over time, or with repeated treatment sessions of Bt, and whether a possible loss of effectiveness occurs in all clinical domains. </p> <p>Finally, in conducting this systematic review, we were faced with the fact that there is no defined core outcome set in cervical dystonia research, as there are for other areas (<a href="./references#CD004312-bbs2-0077" title="TugwellP , BoersM , BrooksP , SimonL , StrandV , IdzerdaL . OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials2007;8:38.">Tugwell 2007</a>). To promote research in this field, and to support the clinical effectiveness of botulinum toxin, it would be relevant to define a set of core outcome measures, and include it in future research, via well‐established methodology, to determine the inclusion of participant‐reported outcomes (<a href="./references#CD004312-bbs2-0050" title="MacefieldRC , JacobsM , KorfageIJ , NicklinJ , WhistanceRN , BrookesST , et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials2014;15:49.">Macefield 2014</a>). </p> <p>Given the high degree of uncertainty in the results, mainly due to the low statistical power of the analysis, future efforts to update this review would be justified, as long as new trials are published. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004312-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004312-sec-0008"></div> <div class="table" id="CD004312-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Botulinum toxin type A compared to anticholinergics for cervical dystonia</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p>Botulinum toxin type A<b>compared to anticholinergics for cervical dystonia</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cervical dystonia<br/><b>Setting:</b> any<br/><b>Intervention:</b> botulinum toxin type A (BtA)<br/><b>Comparison:</b> anticholinergics (trihexyphenidyl) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With anticholinergics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With BtA</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia‐specific improvement</b> </p> <p><i>assessed with TWSTRS disability subscale (0 to 33; higher = more disability)</i> </p> <p>follow‐up: 12 weeks<br/>№ of participants: 66 (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median cervical dystonia‐specific improvement with anticholinergics was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 points higher<br/>(0.68 higher to 4.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of BtA on cervical dystonia‐specific improvement compared with trihexyphenidyl. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p> <ul id="CD004312-list-0001"> <li> <p>Participants in the BtA arm reported 31 adverse events</p> </li> <li> <p>Participants in the trihexyphenidyl arm reported 76 adverse events.</p> </li> <li> <p>No serious adverse events was reported.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective evaluation of clinical status</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia‐specific pain</b> </p> <p><i>assessed with TWSTRS pain subcale (0 to 20; higher = more pain)</i> </p> <p>follow‐up: 12 weeks</p> <p>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>The study authors reported the mean improvement was 1 point in the trihexyphenidyl arm, and 3 points in the BtA arm. </p> <p>No measure of dispersion was given for this difference, and according to the authors it did not reach statistical significance. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p><i>assessed with MOS‐Quality of Life general health perception subscale (100‐points; higher = better)</i> </p> <p>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>The study authors reported the median change was ‐4 in the trihexyphenidyl arm, and +2 in the BtA arm). </p> <p>For the difference in medians, the authors only provide: 95% CI: 4 to 12, p‐value = 0.0023. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tolerability</b> </p> <p><i>assessed by dropouts due to adverse events</i><br/>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.04 to 3.04) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain whether botulinum toxin type A results in less tolerability (more dropouts) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0%<br/>(0.4 to 27.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1% fewer<br/>(8.7 fewer to 18.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of effect</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>MD:</b> mean difference; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>TWSTRS</b>: Toronto Western Spasmodic Torticollis Rating Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to serious imprecision, as the optimal information size was not reached<br/><sup>b</sup>Downgraded one level due to study limitations; concerns with allocation procedures, blinding of participants and personnel, and for‐profit bias<br/><sup>c</sup>The total number of participants included was less than that required by sample size calculation, and the confidence interval included both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004312-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004312-sec-0009"></div> <p>This review is an update of a Cochrane Review evaluating the efficacy and safety of botulinum toxin type A (BtA) versus anticholinergic drugs in the treatment of cervical dystonia (<a href="./references#CD004312-bbs2-0083" title="CostaJ , Espírito‐SantoCC , BorgesAA , MooreP , FerreiraJ , CoelhoMM , et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD004312. [DOI: 10.1002/14651858.CD004312.pub2]">Costa 2005</a>). </p> <section id="CD004312-sec-0010"> <h3 class="title" id="CD004312-sec-0010">Description of the condition</h3> <p>See <a href="#CD004312-tbl-0002">Table 1</a> for glossary of terms. </p> <div class="table" id="CD004312-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Botulinum toxin type A (BtA)‐non‐responsive</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People who do not experience the expected benefit from treatment with botulinum toxin type A </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cervical dystonia or spasmodic torticollis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chemodenervation</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse, and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dysphagia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discomfort or difficulty when swallowing.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dystonia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A painful and disabling disorder, characterised by painful, involuntary posturing of the affected body region(s). </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Electromyography (EMG)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐naive</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People who have been treated in the past with botulinum toxin.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Voluntary action</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Movements that people are able to control, start, and stop when they want to.</p> </td> </tr> </tbody> </table> </div> <p>Dystonia is the third most common movement disorder, after Parkinson’s disease and essential tremor, with an overall prevalence of 164 per million (<a href="./references#CD004312-bbs2-0070" title="SteevesTD , DayL , DykemanJ , JetteN , PringsheimT . The prevalence of primary dystonia: A systematic review and meta‐analysis. Movement Disorders 2012 Dec;27(14):1789-96.">Steeves 2012</a>). Dystonia syndromes are a group of disabling, painful disorders, characterised by involuntary, sustained or intermittent muscle contractions, causing abnormal, often repetitive, movements or postures of the face, neck, trunk, or limbs (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>). Dystonic movements are typically patterned or twisting, and are often initiated or worsened by voluntary action (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>). These neurological disorders can be classified, based on topographic distribution, including focal dystonia (one body region, e.g. cervical dystonia and blepharospasm), segmental dystonia (two or more adjacent regions, e.g. hemifacial spasm), multifocal dystonia (two or more nonadjacent regions), hemidystonia (ipsilateral regions), and generalised dystonia (trunk and two or more other regions; (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>; <a href="./references#CD004312-bbs2-0073" title="TarsyD , SimonDK . Dystonia. New England Journal of Medicine2006;355:818-29.">Tarsy 2006</a>)). </p> <p>Focal dystonia is a highly disabling movement disorder, with serious functional and social impairment. Close to half of the people with it quit work by the age of forty, or retire early, and 10 years later, only 25% are working, compared to 62% of the general population (<a href="./references#CD004312-bbs2-0082" title="ZoonsE , DijkgraafMGW , DijkJM , vVan SchaikIN , TijssenMA . Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. Neurology2012;259(12):2519–26.">Zoons 2012</a>). Moreover, health‐related quality of life is significantly diminished, mainly attributable to depression and anxiety, with scores comparable to people with multiple sclerosis, Parkinson’s disease, or stroke (<a href="./references#CD004312-bbs2-0082" title="ZoonsE , DijkgraafMGW , DijkJM , vVan SchaikIN , TijssenMA . Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. Neurology2012;259(12):2519–26.">Zoons 2012</a>). </p> <p>Cervical dystonia, also called spasmodic torticollis, is the most common form of adult‐onset focal dystonia, with estimates from population studies ranging from 57 per million in Europe (<a href="./references#CD004312-bbs2-0024" title="ESDE 2000. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. Journal of Neurology2000;247:787-92.">ESDE 2000</a>), to as high as 280 per million in the USA (<a href="./references#CD004312-bbs2-0045" title="JankovicJ , TsuiJ , BergeronC . Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism &amp; Related Disorders2007;13(7):411–6.">Jancovic 2007</a>). It typically has its onset in the fifth decade (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>), and affects more women than men (<a href="./references#CD004312-bbs2-0017" title="DefazioG , JankovicJ , GielJL , PapapetropoulosS . Descriptive epidemiology of cervical dystonia. Tremor and Other Hyperkinetic Movements2013;3:tre-03-193-4374-2.">Defazio 2013</a>). This condition is characterised by abnormal movements of the head, neck, and shoulder, resulting in posturing of the head away from its normal central position (<a href="./references#CD004312-bbs2-0029" title="FoltzEL , KnoppLM , WardAA . Experimental spasmodic torticollis. Journal of Neurosurgery1959;16:55-72.">Foltz 1959</a>). It presents frequently with sustained abnormal posture, spasm, jerks, tremor, or a combination of these features. Neck or shoulder pain, or both, occur in more than 70% of people with cervical dystonia (<a href="./references#CD004312-bbs2-0013" title="ChanJ , BrinMF , FanhS . Idiopathic cervical dystonia: clinical characteristics. Movement Disorders1991;6:119-26.">Chan 1991</a>; <a href="./references#CD004312-bbs2-0073" title="TarsyD , SimonDK . Dystonia. New England Journal of Medicine2006;355:818-29.">Tarsy 2006</a>). </p> <p>Cervical dystonia can be classified according to the dominant head position, with the most common type involving horizontal turning, the so‐called rotatory (or simple) torticollis (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>; <a href="./references#CD004312-bbs2-0013" title="ChanJ , BrinMF , FanhS . Idiopathic cervical dystonia: clinical characteristics. Movement Disorders1991;6:119-26.">Chan 1991</a>). Other common patterns include laterocollis (tilt to one side), retrocollis (tilt upwards resulting in neck extension), and anterocollis (tilt downwards resulting in neck flexion). Complex torticollis, a combination of these abnormal patterns, is frequently found in clinical practice. </p> <p>The aetiology of most forms of dystonia is still not fully understood, with the exception of early‐onset dystonia, for which a hereditary aetiology is common (<a href="./references#CD004312-bbs2-0007" title="BalintB , BhatiaKP . Isolated and combined dystonia syndromes – an update on new genes and their phenotypes. European Journal of Neurology2015;22(4):610-7.">Balint 2015</a>). In most cases of focal adult‐onset dystonia, such as cervical dystonia, the pathophysiology is generally considered to result from inhibition of the central nervous system (CNS) at multiple levels, resulting in abnormal sensorimotor integration (<a href="./references#CD004312-bbs2-0034" title="HallettM . The neurophysiology of dystonia. Archives of Neurology1998;55(5):601-3.">Hallett 1998</a>). Cervical dystonia can also be secondary to brain injury, infections of the CNS, drugs (such as levodopa or antipsychotics), toxins, vascular or neoplastic disorders; it may also be psychogenic (i.e. functional; (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>)). Although most cases of cervical dystonia are currently classified as idiopathic, it should be noted that some may come to be reclassified as inherited, since new gene discoveries are under investigation (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>; <a href="./references#CD004312-bbs2-0007" title="BalintB , BhatiaKP . Isolated and combined dystonia syndromes – an update on new genes and their phenotypes. European Journal of Neurology2015;22(4):610-7.">Balint 2015</a>). </p> <p>The natural course of cervical dystonia remains unclear, although it typically worsens over time. The clinical presentation in adults seldom progresses to generalised dystonia, although it often extends to adjacent body regions. For most individuals, cervical dystonia is a life‐long disorder, with only about 10% undergoing spontaneous remissions (<a href="./references#CD004312-bbs2-0043" title="JahnanshahiM , Marion M-H, MarsdenCD . Natural history of adult-onset idiopathic torticollis. Archives of Neurology1990;47:548-52.">Jahnanshahi 1990</a>). </p> <p>To date, no curative or disorder‐modifying treatments are available for cervical dystonia.</p> </section> <section id="CD004312-sec-0011"> <h3 class="title" id="CD004312-sec-0011">Description of the intervention</h3> <p>Botulinum toxin is a powerful biological toxin produced by <i>Clostridium botulinum</i>. The active form of botulinum toxin is a di‐chain polypeptide composed of two chains: a heavy chain (100 kDa) and a light chain (50 kDa); by associating with certain auxiliary proteins (haemagglutinins and non‐haemagglutinins), the toxin forms a non‐covalent multimeric complex of variable size (<a href="./references#CD004312-bbs2-0066" title="SimpsonLL . Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology2004;44:167-93.">Simpson 2004</a>). The nontoxic proteins aid the formation of neutralising antibodies, though beyond this, their role is unclear (<a href="./references#CD004312-bbs2-0030" title="FrevertJ , DresslerD . Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Biologics: Targets &amp; Therapy2010;4:325-32.">Frevert 2010</a>). Botulinim toxin binds to peripheral cholinergic nerve terminals of the neuromuscular junction, as well as sympathetic ganglionic, parasympathetic ganglionic, and postganglionic terminals (<a href="https://archie.cochrane.org/sections/documents/view?document=032503031700542198&amp;format=JATS#REF-Simpson-2004" target="_blank">Simpson 2004</a>). After binding to an acceptor protein, botulinum toxin is endocytosed at the presynaptic membrane of acetylcholine nerve terminals (<a href="https://archie.cochrane.org/sections/documents/view?document=032503031700542198&amp;format=JATS#REF-Pellizzari-1999" target="_blank">Pellizzari 1999</a>). By action of the N‐terminal on the heavy chain, a pore is formed on the endocytic membrane, which permits the release of the light chain into the cytosol. This light chain, which is a zinc protease, performs the key action of the botulinum toxin, by cleaving soluble N‐ethylmaleimide‐sensitive factor attachment receptor proteins (SNARE proteins; (<a href="https://archie.cochrane.org/sections/documents/view?document=032503031700542198&amp;format=JATS#REF-Pellizzari-1999" target="_blank">Pellizzari 1999</a>)). </p> <p>SNAREs are docking proteins for acetylcholine vesicles that allow for the release of acetylcholine into the synaptic cleft (<a href="./references#CD004312-bbs2-0054" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68.">Pellizzari 1999</a>). The overall effect of Bt is local chemodenervation by the temporary blockade of acetylcholine release at cholinergic synapses. Temporary synapses are consequently formed via the process of axonal sprouting (<a href="./references#CD004312-bbs2-0023" title="DuchenLW . An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. Journal of Neurological Sciences1971;14:47-60.">Duchen 1971</a>; <a href="./references#CD004312-bbs2-0041" title="HollandRL , BrownMC . Nerve growth in botulinum toxin poisoned muscles. Neuroscience1981;6:1167–79.">Holland 1981</a>; <a href="./references#CD004312-bbs2-0047" title="JuzansP , ComellaJ , MolgoJ , FailleL , Angaut-PetitD . Nerve terminal sprouting in botulinum type A treated mouse levator auris longus muscle. Neuromuscular Disorders: NMD1996;6(3):177-85.">Juzans 1996</a>). </p> <p>There are seven immunologically distinct botulinum toxin serotypes (labelled A to G). These different Bt serotypes cleave specific SNARE proteins. Serotype A cleaves SNARE protein SNAP 25, located on the inner membrane, and serotype B targets synaptobrevin, located on the vesicular membrane (<a href="./references#CD004312-bbs2-0054" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68.">Pellizzari 1999</a>). </p> <p>Botulinum toxin is injected into the muscles involved in dystonia, with or without guidance by either electromyography (EMG) or ultrasound. As a general rule, the number of muscles injected is tailored to the severity of the case in question, and the number of injection sites per muscle is determined by the mass of the muscle. Within roughly three months after injection of botulinum toxin into skeletal muscle, the nerve terminal resumes exocytosis, and the muscle returns to its baseline clinical function, showing a wearing‐off response from the Bt injection (<a href="./references#CD004312-bbs2-0046" title="JankovicJ . Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(7):951-7.">Jankovic 2004</a>). Eventually, the muscle paralysis subsides; this is associated with the formation of new sprouts capable of neurotransmission. Over time, synaptic activity resumes in the original nerve terminals, leading to sprout regression (<a href="./references#CD004312-bbs2-0018" title="dePaivaA , MeunierFA , MolgóJ , AokiKR , DollyJO . Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America1999;96:3200–5.">de Paiva 1999</a>). </p> <p>Currently there are two commercially available botulinum toxin serotypes – botulinum toxin type A (BtA) and botulinum toxin type B (BtB). The following products are commonly available (three BtA and one BtB): onabotulinumtoxinA (Botox, Allergan Inc., Irvine, CA, USA), abobotulinumtoxinA (Dysport, Reloxin, or Azzalure, Ipsen Pharma, Boulogne Billancourt, France), incobotulinumtoxinA (Xeomin or Bocoture Merz GmbH, Frankfurt, Germany), and rimabotulinumtoxinB (Myobloc or Neurobloc, Solstice Neurosciences Inc., Louisville, KY, USA). Other BtA formulations are available in more restricted markets, and are yet to receive a generic name: Prosigne or Lantox (Lanzhou Institute of Biological Products, China), PurTox (Mentor Worldwide LLC, Santa Barbara, CA, USA), and Neuronox (Medy‐Tox Inc, South Korea; (<a href="./references#CD004312-bbs2-0078" title="WalkerTJ , DayanSH . Comparison and overview of currently available neurotoxins. Journal of Clinical and Aesthetic Dermatology2014;7(2):31-9.">Walker 2014</a>)). </p> <p>Anticholinergic drugs are chemicals that interfere with signal transmission mediated by acetylcholine molecules and acetylcholine receptors. These molecules reduce the effect of acetylcholine by competitively inhibiting its binding to acetylcholine receptors. Acetylcholine receptors exist in the central nervous system and in the periphery, including the peripheral nervous system, the autonomic effector cells, and others cell types, such as the vascular endothelium (<a href="./references#CD004312-bbs2-0040" title="Hilal-DandanR , BruntonL . Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. New York: McGraw Hill Professional, 2013.">Hilal‐Dandan 2013</a>). </p> <p>These components are classified according to the receptors with which they have the most affinity. The anti‐muscarinic agents operate on muscarinic acetylcholine receptors, and the anti‐nicotinic agents on the nicotine acetylcholine receptors. Only the former are used to treat dystonia. Of the anti‐muscarinic anticholinergic drugs, very few have good bio‐availability within the central nervous system. A subclass of tertiary‐amine muscarinic receptor antagonists is the exception, and compounds, such as trihexyphenidyl (non‐proprietary), biperiden (Akineton®, Abbott, Chicago, USA), benztropine (non‐proprietary), procyclidine (non‐proprietary), and diphenhydramine (non‐proprietary) have good penetration into the central nervous system (<a href="./references#CD004312-bbs2-0040" title="Hilal-DandanR , BruntonL . Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. New York: McGraw Hill Professional, 2013.">Hilal‐Dandan 2013</a>). </p> <p>There are limitations to the use of anticholinergic agents. Although they are administered enterally, making them easy to take and sometimes preferred, they must be taken daily, and are often part of complex treatment regimen (<a href="./references#CD004312-bbs2-0026" title="FahnS . Systemic therapy of dystonia. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques1987;14(S3):528-32.">Fahn 1987</a>). They are systemically absorbed, meaning that their pharmacological effects can be felt diffusely across body systems where cholinergic receptors exist, including the central, peripheral, and autonomic nervous system. This characteristic is sometimes leveraged to treat forms of dystonia that affect several muscles and segments, but anticholinergics are avoided when possible, as the resulting side effects threaten the tolerability and limit the dosages that can be used (<a href="./references#CD004312-bbs2-0025" title="FahnS . High dosage anticholinergic therapy in dystonia. Neurology1983;33(10):1255.">Fahn 1983</a>). Some of these side effects include dryness of the mouth and other mucosae, vision alterations, bower and bladder difficulties, increased heart rate, sedation, and confusion or disorientation. These are especially relevant and bothersome in older adults and people with cognitive problems (<a href="./references#CD004312-bbs2-0074" title="TaylorAE , LangAE , Saint-CyrJA , RileyDE , RanawayaR . Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clinical Neuropharmacology1991;14(1):62-77.">Taylor 1991</a>). </p> </section> <section id="CD004312-sec-0012"> <h3 class="title" id="CD004312-sec-0012">How the intervention might work</h3> <p>The therapeutic potential of all Bt serotypes derives from their ability to inhibit the release of acetylcholine from the presynaptic nerve terminal into the synaptic cleft, causing local chemodenervation (<a href="./references#CD004312-bbs2-0046" title="JankovicJ . Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(7):951-7.">Jankovic 2004</a>). Recent research has also suggested that Bt is active at multiple levels, namely sensory nerve terminals, and muscle spindles, which leads to a reduction in sensory input and fewer muscle contractions (<a href="./references#CD004312-bbs2-0027" title="FilippiGM , ErricoP , SantarelliR , BagoliniB , ManniE . Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-laryngologica1993;113:400–4.">Filippi 1993</a>; <a href="./references#CD004312-bbs2-0052" title="MatakI , LackoviZ . Botulinum neurotoxin type A: actions beyond SNAP-25?Toxicology2015;335:79-84.">Matak 2015</a>; <a href="./references#CD004312-bbs2-0061" title="RosalesRL , ArimuraK , TakenakaS , OsameM . Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle &amp; Nerve1996;19:488–96.">Rosales 1996</a>; <a href="./references#CD004312-bbs2-0062" title="RosalesRL , DresslerD . On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology2010;17:71–80.">Rosales 2010</a>). </p> <p>In cervical dystonia, and in dystonia in general, the biological basis for the therapeutic effect of anticholinergic drugs is not completely understood. After crossing the blood‐brain barrier, these compounds are thought to act on the acetylcholine receptors that mediate the response to the intrinsic cholinergic connections present in the neostriatum. </p> </section> <section id="CD004312-sec-0013"> <h3 class="title" id="CD004312-sec-0013">Why it is important to do this review</h3> <p>BtA is the toxin serotype that has been most intensively studied and approved for the treatment of a number of focal dystonias (<a href="./references#CD004312-bbs2-0021" title="DuarteGS , RodriguesFB , CastelãoM , MarquesRE , FerreiraJ , SampaioC , MooreAP , CostaJ . Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD004899. [DOI: 10.1002/14651858.CD004899.pub3]">Duarte 2020</a>; <a href="./references#CD004312-bbs2-0022" title="DuarteGS , RodriguesFB , MarquesRE , CastelãoM , FerreiraJ , SampaioC , MooreAP , CostaJ . Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD004900. [DOI: 10.1002/14651858.CD004900.pub3]">Duarte 2020a</a>; <a href="./references#CD004312-bbs2-0060" title="RodriguesFB , DuarteGS , MarquesRE , CastelãoM , FerreiraJ , SampaioC , MooreAP , CostaJ . Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub4]">Rodrigues 2020</a>). BtA is considered first‐line therapy for cervical dystonia (<a href="./references#CD004312-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863-73.">Albanese 2013</a>; <a href="./references#CD004312-bbs2-0012" title="CastelãoM , MarquesRE , DuarteGS , RodriguesFB , FerreiraJ , SampaioC , et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub3] [CD003633]">Castelão 2017</a>; <a href="./references#CD004312-bbs2-0060" title="RodriguesFB , DuarteGS , MarquesRE , CastelãoM , FerreiraJ , SampaioC , MooreAP , CostaJ . Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub4]">Rodrigues 2020</a>). BtB has also been shown to be efficacious, but it has a different safety profile (<a href="./references#CD004312-bbs2-0019" title="DuarteGS , CastelãoM , RodriguesFB , MarquesRE , FerreiraJ , SampaioC , et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD004314. [DOI: 10.1002/14651858.CD004314.pub3]">Duarte 2016</a>; <a href="./references#CD004312-bbs2-0051" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD004315. [DOI: 10.1002/14651858.CD004315.pub3] [PMID: 27176573]">Marques 2016</a>). Even in moderately severe dystonia, there is evidence that people attach a considerable expectation of harm due to botulinum toxin (<a href="./references#CD004312-bbs2-0020" title="DuarteGD , RodriguesFB , FerreiraJJ , CostaJ . Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?Parkinsonism &amp; Related Disorders2018;56:16-9. [DOI: 10.1016/j.parkreldis.2018.06.017]">Duarte 2018</a>). Since anticholinergics were the most widely accepted treatment before BtA became available, it is relevant to understand how these two treatments compare. </p> <p>Since the release of the original review in 2005, no new trials have been published, but Cochrane’s criteria for evaluating risk of bias and the certainty of the evidence have evolved and been updated. Therefore, the review authors considered it important to update this review (<a href="./references#CD004312-bbs2-0083" title="CostaJ , Espírito‐SantoCC , BorgesAA , MooreP , FerreiraJ , CoelhoMM , et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD004312. [DOI: 10.1002/14651858.CD004312.pub2]">Costa 2005</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004312-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004312-sec-0014"></div> <p>To compare the efficacy, safety, and tolerability of botulinum toxin type A versus anticholinergics in adults with cervical dystonia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004312-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004312-sec-0015"></div> <section id="CD004312-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004312-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), that were double‐blind, parallel‐designed, and which assessed the efficacy or safety, or both, of single or multiple doses of botulinum toxin type A (BtA) treatment versus anticholinergics, for any duration, in people with cervical dystonia. We excluded non‐parallel study designs, namely cross‐over trials, due to uncertainty about whether this type of study design was appropriate to study people with cervical dystonia, as well as methodological concerns with regards to detection and performance bias. </p> <p>There were no restrictions regarding the number of participants recruited to trials, or the number of recruitment centres. </p> </section> <section id="CD004312-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (i.e. ≥ 18 years of age), in any setting, with a clinical diagnosis of idiopathic cervical dystonia, made by any physician, specialist, or other healthcare worker. We allowed trials that enrolled participants with any form of cervical dystonia, and additional, or widespread dystonias. Participants could have had prior exposure to BtA, and could be taking any concomitant medications, if they were on stable regimens. </p> </section> <section id="CD004312-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Intramuscular injections of BtA compared to anticholinergic drugs. We allowed all administration schedules and injection techniques, performed with or without guidance by either electromyography (EMG) or ultrasound. </p> </section> <section id="CD004312-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004312-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD004312-sec-0022"> <h6 class="title">Cervical dystonia‐specific improvement</h6> <p>Overall improvement on any validated symptomatic rating scale, such as the Cervical Dystonia Severity Scale (CDSS), Tsui scale, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS total score), or TWSTRS severity and disability subscales, measured 12 weeks after treatment (<a href="./references#CD004312-bbs2-0015" title="ConskyES , LangAE . Clinical Assessments of Patients with Cervical Dystonia. Jankovic J, Hallett M edition. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc, 1994.">Consky 1994</a>). </p> </section> <section id="CD004312-sec-0023"> <h6 class="title">Adverse events</h6> <p>The proportion of participants with any adverse event, measured at any point during follow‐up. In this item, we also evaluated adverse events of special interest, such as sore throat or dry mouth, neck weakness, dysphagia, injection site pain, voice change, or systemic complaints (e.g. diffuse muscle weakness, malaise, dizziness, or headache), measured at any point during follow‐up. </p> </section> </section> <section id="CD004312-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD004312-sec-0025"> <h6 class="title">Subjective evaluation of clinical status</h6> <p>Evaluated by either participants, clinicians, or both, assessed with validated assessment tools, such as the Patient Subjective Assessment of Change, Patient Global Assessment of Improvement, Patient Evaluation of Global Response (PEGR), Patient and Physician Global Assessment of Change, Investigator Global Assessment of Efficacy (IGAE), Physician Global Assessment of Change (PGAC), or a visual analogue scale (VAS) for symptom severity, measured between at 12 weeks. </p> </section> <section id="CD004312-sec-0026"> <h6 class="title">Cervical dystonia‐related pain</h6> <p>Assessed with validated assessment tools, such as the Patient Assessment of Pain, TWSTRS pain subscale, and VAS pain score, measured at 12 weeks. </p> </section> <section id="CD004312-sec-0027"> <h6 class="title">Health‐related quality of life</h6> <p>Assessed with validated assessment tools, such as the Short Form‐36 (SF‐36) Quality‐of‐life questionnaire or Cervical Dystonia Impact Profile (CDIP)‐58 scale, measured at any point during follow‐up. </p> </section> <section id="CD004312-sec-0028"> <h6 class="title">Tolerability</h6> <p>We defined tolerability as the number of participants who dropped out due to adverse events, measured at any point during follow‐up. </p> </section> <section id="CD004312-sec-0029"> <h6 class="title">Duration of effect</h6> <p>Assessed by the number of days until the need for reinjection, or the effect was waning.</p> </section> </section> </section> </section> <section id="CD004312-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>For this update, we expanded the search strategy to capture all the search terms for BtA formulations that were currently available. The search strategy was designed to include other botulinum toxin formulations and other dystonic disorders that are also under current revision by the Cochrane Movement Disorders group. </p> <section id="CD004312-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We ran the final search for the original version of this review in June 2003, based on the search strategy developed for Cochrane Movement Disorders to identify all papers since 1977, the first year that botulinum toxin was used therapeutically for any condition. The search for the current update was run for the last time in July 2020. </p> <p>We developed detailed search strategies for each database searched. Please see <a href="./appendices#CD004312-sec-0082">Appendix 1</a> for the Cochrane Central Register of Controlled Trials (CENTRAL) strategy, <a href="./appendices#CD004312-sec-0083">Appendix 2</a> for the MEDLINE search strategy, and <a href="./appendices#CD004312-sec-0084">Appendix 3</a> for the Embase strategy. </p> <p>We assessed non‐English language papers, translated them as necessary, and evaluated them for inclusion. </p> <p>We did not search trials registries.</p> <section id="CD004312-sec-0032"> <h5 class="title">Databases searched</h5> <p> <ul id="CD004312-list-0002"> <li> <p>Cochrane Movement Disorders' Trials Register (June 2003);</p> </li> <li> <p>CENTRAL (2020, Issue 6) in the Cochrane Library (searched July 2020);</p> </li> <li> <p>MEDLINE (1977 to July 2020);</p> </li> <li> <p>Embase (1977 to July 2020).</p> </li> </ul> </p> </section> </section> <section id="CD004312-sec-0033"> <h4 class="title">Searching other resources</h4> <p>The search strategy also included:</p> <p> <ul id="CD004312-list-0003"> <li> <p>screening reference lists of identified trials and review articles concerning botulinum toxin; </p> </li> <li> <p>hand searching abstracts of international congresses relevant in the fields of movement disorders and botulinum toxins (American Academy of Neurology, Movement Disorders Society, International Association of Parkinsonism and Related Disorders, and International Neurotoxin Association (1985 to September 2018)); </p> </li> <li> <p>personal communication with other researchers in the field;</p> </li> <li> <p>contact with drug manufacturers.</p> </li> </ul> </p> </section> </section> <section id="CD004312-sec-0034"> <h3 class="title" id="CD004312-sec-0034">Data collection and analysis</h3> <section id="CD004312-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened all titles and abstracts identified from the searches to determine which ones met the inclusion criteria. We retrieved, in full text, any papers identified as potentially relevant by at least one review author, or those without an available abstract. Two review authors independently screened full‐text articles, with discrepancies resolved by discussion until they reached consensus; they consulted a third review author when necessary. We linked multiple publications of the same trial under a single study ID in the review. We outlined the screening and selection process in a PRISMA flow chart (<a href="./references#CD004312-bbs2-0048" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6:e1000100.">Liberati 2009</a>). See <a href="#CD004312-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004312-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (2020 search)" data-id="CD004312-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (2020 search)</p> </div> </div> </div> </section> <section id="CD004312-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently from included studies, using a piloted data extraction form. We resolved any discrepancies by discussion until we reached consensus; we consulted a third review author when necessary. Data extracted included the following items from each study. </p> <p> <ul id="CD004312-list-0004"> <li> <p>Participants: inclusion and exclusion criteria, demographics and clinical baseline characteristics, number and reasons for dropouts, exclusions, and loss to follow‐up, if any </p> </li> <li> <p>Interventions: full description of intervention, duration of treatment period and follow‐up, providers, and co‐interventions, if any </p> </li> <li> <p>Comparisons: number of participants randomised to each arm, compliance and dropouts, and ability to perform an intention‐to‐treat analysis </p> </li> <li> <p>Outcomes: definition of outcomes, use of validated measurement tools, time‐point measurements, change from baseline or post‐interventional measures, and missing outcomes, if any </p> </li> <li> <p>Study design: interventional, randomised, controlled, double‐blind</p> </li> </ul> </p> <p>Whenever necessary, we contacted authors of the trials for further information and unpublished data. </p> </section> <section id="CD004312-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies according to the domains described in the Cochrane tool for assessing risk of bias, and classified the risk of bias for each domain as high, unclear, or low, and the overall assessment as high or low (<a href="./references#CD004312-bbs2-0037" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011a</a>). We assessed two further domains, which are described below: enriched population and independent funding. We used the following definitions for each domain in the 'Risk of bias' assessment. </p> <p> <ul id="CD004312-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated); high risk of bias (non‐random process used, e.g. allocation by birth year or by judgement). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). We assessed the method used to conceal allocation to interventions prior to assignment, to determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated); high risk of bias (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). Studies that were not double‐blind were considered at high risk of bias. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study has a clear statement that outcome assessors were unaware of treatment allocation, and ideally describes how this was achieved); unclear risk of bias (study states that outcome assessors were blind to treatment allocation but lacks a clear statement on how it was achieved). We considered studies where outcome assessment was not blinded at high risk of bias. </p> </li> <li> <p>Selective reporting (checking for reporting bias). We assessed whether primary and secondary outcome measures were pre‐specified and whether these were consistent with those reported. We assessed selective reporting as: low risk of bias (studies reporting primary and secondary outcomes); unclear risk of bias (study reporting insufficient information to permit judgement); high risk of bias (not all pre‐specified outcomes reported or only for certain data collection time points). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants did not complete the study, trialist used ‘baseline observation carried forward’ analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> </ul> </p> <p>Additional 'Risk of bias' items</p> <p> <ul id="CD004312-list-0006"> <li> <p>Enriched population. Because the clinical effect of botulinum toxin treatment is easily perceived, participants naive to botulinum toxin are likely to recognise the presence or absence of beneficial clinical effects, or frequent adverse events, or both, effectively revealing the respective allocation arm. It is also relevant that by preferentially including responders to botulinum toxin or excluding non‐responders to botulinum toxin, there is an increased likelihood that these participants would respond more favourably to botulinum toxin than a naive population would. We opted to subdivide this domain in two: preferential enrolment of known positive responders to botulinum toxin; and exclusion of known poor responders to botulinum toxin. </p> <ul id="CD004312-list-0007"> <li> <p>Low risk of bias: at least 70% of trial participants were naive to treatment with botulinum toxin; the trial did not exclude any particular form of cervical dystonia including those associated with a poorer response to botulinum toxin (such as pure anterocollis and retrocollis). </p> </li> <li> <p>Unclear risk of bias: the trial did not make explicit the percentage of participants who were known to be botulinum toxin naive. </p> </li> <li> <p>High risk of bias: arbitrarily defined as more than 30% of participants non‐naive to botulinum toxin; explicit exclusion of people with forms of cervical dystonia associated with a poorer response to botulinum toxin. </p> </li> </ul> </li> <li> <p>For‐profit bias. In order to assess the study source of funding, we added this domain in place of the ‘other bias’ domain. </p> <ul id="CD004312-list-0008"> <li> <p>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for‐profit support that may introduce bias into trial design, conduct, or trial results. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not be free of for‐profit bias, as the trial did not provide any information on clinical trial support or sponsorship. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </li> </ul> </p> <p><a href="./references#CD004312-bbs2-0037" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011a</a> </p> <p> <ul id="CD004312-list-0009"> <li> <p>Corbett 2014</p> </li> </ul> </p> </section> <section id="CD004312-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We compared disorder‐related symptoms at baseline to disorder‐related symptoms at weeks three to six post‐injection in the BtA and anticholinergic arms. We extracted continuous outcomes whenever possible, pooled the data from the studies where adequate, and used them for comparison. </p> <section id="CD004312-sec-0039"> <h5 class="title">Dichotomous data</h5> <p>We based analysis of these data on the number of events and the number of people assessed in the BtA and anticholinergic groups. We used these to calculate the risk ratio (RR) and 95% confidence interval (CI). Computational problems can occur when no events are observed in one or both groups in an individual study. For studies where no events were observed in one or both arms, we added a fixed value of 0.5 to all cells of study results tables. </p> </section> <section id="CD004312-sec-0040"> <h5 class="title">Continuous data</h5> <p>We based analysis of these data on the mean, standard deviation (SD), and number of participants assessed for both the BtA and anticholinergic groups to calculate mean difference (MD) and 95% CI. Where the MD was reported without individual group data, we used this to report the study results. If more than one study measured the same outcome using different validated tools, we planned to calculated the standardised mean difference (SMD), namely Hedges’ (adjusted) g and 95% CI (<a href="./references#CD004312-bbs2-0035" title="HedgesLV , OlkinI . Statistical Methods for Meta-Analysis. San Diego, California: Academic Press, Inc, 1985.">Hedges 1985</a>). For interpretation of effect sizes with SMDs, we used a rule of thumb to define a small effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a large effect (SMD = 0.8; (<a href="./references#CD004312-bbs2-0014" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.">Cohen 1988</a>)). If necessary for comparison, we planned to dichotomise rating scales, using each study author's own criteria for improvement or no improvement. </p> </section> <section id="CD004312-sec-0041"> <h5 class="title">Time‐to‐event data</h5> <p>We planned to analyse these data (duration of treatment effect) based on log hazard ratios (HR) and standard errors (SE) obtained from results of Cox proportional hazards regression models. We had planned to use these in order to calculate a HR and 95% CI. </p> </section> </section> <section id="CD004312-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>If future included studies have multiple arms with different dosages of botulinum toxin, we will combine all groups to create a single pair‐wise comparison, using the Review Manager 5 (RevMan 5) calculator (<a href="./references#CD004312-bbs2-0058" title="Nordic Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), according to the methods suggested by Cochrane (<a href="./references#CD004312-bbs2-0038" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011b</a>). We will create a single, pair‐wise comparison when multiple treatment groups use different interventions (e.g. onabotulinumtoxinA and abobotulinumtoxinA) but the same comparator. </p> <p>This method combines all relevant intervention groups of the study into a single group, and all relevant control groups into a single control group. This approach avoids duplication of the control group that would happen if multiple comparisons (e.g. BtA dose 1 versus placebo; BtA dose 2 versus placebo) were included in the meta‐analysis, and the loss of information if one dose group was chosen to the detriment of the others. If applicable, we will explore the effect of dose in subgroup analysis. </p> <p>For dichotomous outcomes, we will sum both the sample sizes and the numbers of people with events across groups. For continuous outcomes, we will combine means and standard deviations using a pooled mean or SD (<a href="./references#CD004312-bbs2-0038" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011b</a>; <a href="./references#CD004312-bbs2-0039" title="HigginsJPT , and DeeksJJ , editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011c</a>). </p> </section> <section id="CD004312-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>For future updates, if we include studies with missing outcome or summary data, we will use imputation methods to derive the missing data (where possible) and report any assumptions in the review. We will carry out sensitivity analyses to investigate the effects of any imputed data on pooled effect estimates. </p> <p>As a first option, we will use the available information (e.g. standard error (SE), 95% CI, or exact P value) to recover the missing data algebraically (<a href="./references#CD004312-bbs2-0038" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011b</a>; <a href="./references#CD004312-bbs2-0039" title="HigginsJPT , and DeeksJJ , editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011c</a>; <a href="./references#CD004312-bbs2-0081" title="WiebeN , VandermeerB , PlattRW , KlassenTP , MoherD , BarrowmanNJ . A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology2006;59(4):342-53.">Wiebe 2006</a>). When change from baseline SD is not reported, or we are unable to extract it, we will create a correlation coefficient based on another study in the review, and use it to impute a change from baseline SD (<a href="./references#CD004312-bbs2-0003" title="AbramsKR , GilliesCL , LambertPC . Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine2005;24:3823-44.">Abrams 2005</a>; <a href="./references#CD004312-bbs2-0028" title="FollmannD , ElliottP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45:769-73.">Follmann 1992</a>; <a href="./references#CD004312-bbs2-0038" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011b</a>). </p> <p>If we are unable to use studies from the review to calculate a correlation coefficient, and if there is at least one sufficiently large and similar study, we will use a single imputation, based on this study (<a href="./references#CD004312-bbs2-0031" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10.">Furukawa 2006</a>; <a href="./references#CD004312-bbs2-0038" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Higgins 2011b</a>). </p> <p>Lastly, if there are sufficient included studies with complete information, we will use multiple imputation methods to derive missing data (<a href="./references#CD004312-bbs2-0010" title="CarpenterJ , KenwardM . Multiple Imputation and its Application. Chichester: Wiley, 2013.">Carpenter 2013</a>; <a href="./references#CD004312-bbs2-0063" title="RubinDB , SchenkerN . Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine1991;10:585–98.">Rubin 1991</a>). </p> <p>If none of these methods prove successful, we will conduct a narrative synthesis for the data in question. </p> </section> <section id="CD004312-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>In future updates, if we include more studies, we will assess whether they are similar enough to enable us to pool the data in a meta‐analysis. We will assess the degree of heterogeneity by visual inspection of forest plots, and by examining the Chi² test for heterogeneity (<a href="./references#CD004312-bbs2-0016" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Deeks 2011</a>). We will quantify heterogeneity using the I² statistic (<a href="./references#CD004312-bbs2-0036" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We will consider an I² value of 50% or more to represent substantial levels of heterogeneity, but will interpret this value in light of the size and direction of effects, and the strength of the evidence for heterogeneity, based on the P value from the Chi² test. </p> </section> <section id="CD004312-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We only included one study in this review, so we did not construct a funnel plot (<a href="./references#CD004312-bbs2-0071" title="SterneJA , EggerM . Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology2001;54(10):1046-55.">Sterne 2001</a>), or conduct formal testing of asymmetry, which may indicate publication bias (<a href="./references#CD004312-bbs2-0055" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Comparison of two methods to detect publication bias in meta-analysis. JAMA2006;295(6):676-80.">Peters 2006</a>). Should we include 10 or more studies in future updates, we will undertake these analyses. </p> </section> <section id="CD004312-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We planned to analyse the data using Review Manager 5 (<a href="./references#CD004312-bbs2-0058" title="Nordic Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), Stata version 14 (<a href="./references#CD004312-bbs2-0069" title="Stata. Version 14. College Station, TX, USA: StataCorp, 2015. Available at www.stata.com.">Stata</a>), and Trial Sequential Analysis (<a href="./references#CD004312-bbs2-0075" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa ̇manual.pdf 2011.">Thorlund 2011</a>; <a href="./references#CD004312-bbs2-0076" title="Copenhagen Trial UnitTrial Sequential Analysis. Version 0.9 Beta. Version accessed 3 January 2017. Copenhagen: Copenhagen Trial Unit, 2011. Available at www.ctu.dk/tsa/downloads.aspx.">TSA 2011</a>). </p> <section id="CD004312-sec-0047"> <h5 class="title">Meta‐analysis</h5> <p>In future updates, if we include more studies, we will base the decision to meta‐analyse data on an assessment of whether the interventions in the included trials have similar enough participants, settings, interventions, comparisons, and outcome measures to ensure meaningful conclusions from a statistically pooled result. We will use a random‐effects model for the data synthesis. </p> <p>We will pool effect measures by applying the Mantel‐Haenszel method for dichotomous outcomes, and the inverse‐variance or generic inverse‐variance method for continuous outcomes. If we have the data, we will pool time‐to‐event data using the generic inverse‐variance method. We will present all results with 95% CI. </p> <p>We will calculate the number of participants needed to treat for an additional beneficial outcome (NNTB) and for an additional harmful outcome (NNTH) from meta‐analysis estimates, rather than treating data as if they came from a single trial, as the latter approach is more prone to bias, especially when there are significant imbalances between groups within one or more trials in the meta‐analysis (<a href="./references#CD004312-bbs2-0006" title="AltmanDG , DeeksJJ . Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology2002;2:3.">Altman 2002</a>). We will be cautious when interpreting these findings, since they may be misleading because of variation in the event rates in each trial, differences in the outcomes considered, and differences in clinical setting (<a href="./references#CD004312-bbs2-0068" title="SmeethL , HainesA , EbrahimS . Numbers needed to treat derived from meta-analysis – sometimes informative, usually misleading. BMJ1999;318(7197):1548-51.">Smeeth 1999</a>). </p> <p>Since there were no data to combine, we undertook a narrative approach to synthesise the result. </p> </section> <section id="CD004312-sec-0048"> <h5 class="title">Trial Sequential Analysis</h5> <p>If we include more studies in an update, we will conduct a Trial Sequential Analysis (TSA) to explore whether the cumulative data are of adequate power to evaluate the primary outcomes of the review (<a href="./references#CD004312-bbs2-0079" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61:64-75.">Wetterslev 2008</a>), and calculate a required information size (also known as the 'heterogeneity‐adjusted required information size'; (<a href="./references#CD004312-bbs2-0080" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>)). TSA aims to evaluate whether statistically significant results of meta‐analyses are reliable, by accounting for the required information size (i.e. the number of participants in the meta‐analysis required to accept or reject an intervention effect). The technique is analogous to sequential monitoring boundaries in single trials. TSA adjusts the threshold of statistical significance and has been shown to reduce the risk of random errors due to repetitive testing of accumulating data (<a href="./references#CD004312-bbs2-0042" title="ImbergerG , ThorlundK , GluudC , WetterslevJ . False-positive findings in Cochrane meta-analyses with and without application of Trial Sequential Analysis: an empirical review. BMJ Open2016;6(8):e011890.">Imberger 2016</a>). </p> <p>We will calculate the required information size and compute the trial sequential monitoring boundaries, using the O’Brien‐Fleming approach (<a href="./references#CD004312-bbs2-0053" title="O’BrienPC , FlemingTR . A multiple testing procedure for clinical trials. Biometrics1979;35:549-56.">O'Brien 1979</a>). We will based the required information size on the event proportion or standard deviation in the control group; an assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta‐analysis (<a href="./references#CD004312-bbs2-0044" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14(1):120.">Jakobsen 2014</a>). We will not give any consideration to the risk of bias within trials. </p> <p><a href="./references#CD004312-bbs2-0064" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Schünemann 2011</a><a href="./references#CD004312-bbs2-0032" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version assessed 3 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a> </p> <p> <ul id="CD004312-list-0010"> <li> <p><a href="./references#CD004312-bbs2-0033" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011</a> </p> </li> </ul> </p> <p><a href="./references#CD004312-bbs2-0008" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a> </p> </section> </section> <section id="CD004312-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses for the following areas, independently of the presence of significant heterogeneity. </p> <p> <ul id="CD004312-list-0011"> <li> <p>Different BtA formulations</p> </li> <li> <p>Different anticholinergic agents</p> </li> <li> <p>Different BtA doses, all defined arbitrarily: high (Botox or Xeomin &gt; 200 U; Dysport = 1000 U), medium (Botox or Xeomin 100 U to 200 U; Dysport = 500 U), and low (Botox or Xeomin &lt; 100 U; Dysport = 250 U) </p> </li> <li> <p>EMG‐guided versus non‐EMG‐guided botulinum toxin injection</p> </li> </ul> </p> </section> <section id="CD004312-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to conduct sensitivity analyses for every study for which we applied imputation methods. </p> </section> <section id="CD004312-sec-0051"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Assessing the certainty in the evidence</p> <p>Two review authors independently assessed the evidence for each outcomes using the following domains: study limitations, inconsistency, indirectness, imprecision, and publication bias (<a href="./references#CD004312-bbs2-0064" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Schünemann 2011</a>). In case of disagreement, the authors attempted to reach consensus, consulting an independent third review author if necessary. We used the GRADEpro GDT software tool to assess the certainty, and then exported a 'Summary of findings' table into the review manuscript (<a href="./references#CD004312-bbs2-0032" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version assessed 3 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>To ensure the consistency and reproducibility of GRADE judgements, we applied the following criteria to each domain for each critical outcome. </p> <p> <ul id="CD004312-list-0012"> <li> <p>Study limitations: we downgraded once if more than 30% of the participants were from studies classified as being at a high risk of bias across any domain, with the exception of for‐profit bias. </p> </li> <li> <p>Inconsistency: we downgraded once if heterogeneity was statistically significant, or if the I² value was more than 40%. When we did not perform a meta‐analysis, we downgraded once if trials did not show effects in the same direction. </p> </li> <li> <p>Indirectness: we downgraded once if more than 50% of the participants were outside the target group. </p> </li> <li> <p>Imprecision: we downgraded once if the optimal information size criterion was not met, or alternatively, if it was met but the 95% CI failed to exclude important benefit or important harm (<a href="./references#CD004312-bbs2-0033" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011</a>). </p> </li> <li> <p>Publication bias: we downgraded once where there was direct evidence of publication bias, or if estimates of effect were based on small scale, industry‐sponsored studies, which raised a high index of suspicion of publication bias. </p> </li> </ul> </p> <p>We applied the following definitions to the certainty in the evidence (<a href="./references#CD004312-bbs2-0008" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>): </p> <p> <ul id="CD004312-list-0013"> <li> <p>high certainty: we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p>very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>'Summary of findings' table</p> <p>We included a 'Summary of findings' table to present the main findings of this review in a simple tabular format, based on the results and the GRADE analysis. Version 3 was used for ease of interpretation (<a href="./references#CD004312-bbs2-0011" title="Carrasco-Labra Alonso, Brignardello-Petersen Romina, Santesso Nancy, Neumann Ignacio, Mustafa ReemA , Mbuagbaw Lawrence, Etxeandia Ikobaltzeta Itziar, De Stio Catherine, McCullagh LaurenJ , Alonso-Coello Pablo, Meerpohl JoergJ , Vandvik Per Olav, Brozek JanL , Akl ElieA , Bossuyt Patrick, Churchill Rachel, Glenton Claire, Rosenbaum Sarah, Tugwell Peter, Welch Vivian, Garner Paul, Guyatt Gordon, Schünemann HolgerJ . Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format. Journal of Clinical Epidemiology2016;74:7-18.">Carrasco‐Labra 2016</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004312-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004312-sec-0052"></div> <section id="CD004312-sec-0053"> <h3 class="title">Description of studies</h3> <p>We did not identify any new studies in this update.</p> <p>Overall, we included a single parallel‐designed study, comparing BtA (Dysport) with trihexyphenidyl, with a total of 66 participants with cervical dystonia. </p> <p>See also <a href="./references#CD004312-sec-0094" title="">Characteristics of included studies</a>. </p> <section id="CD004312-sec-0054"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD004312-fig-0001">Figure 1</a>, flow diagram of study selection. </p> <p>We last ran the updated electronic search in July 2020. The search returned 1294 records (459 through CENTRAL; 313 though MEDLINE; 522 through Embase), resulting in 895 records after removing all duplicates. After title and abstract screening, we retrieved two articles for full‐text screening, and only one was eligible for both the qualitative and quantitative syntheses (<a href="./references#CD004312-bbs2-0001" title="BransJW , LindeboomR , SnoekJW , ZwartsMJ , vanWeerdenTW , BruntER , et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology1996;46(4):1066-72. ">Brans 1996</a>). This study was already included in the original review. </p> <p>We did not retrieve any unpublished trials.</p> </section> <section id="CD004312-sec-0055"> <h4 class="title">Included studies</h4> <p>We listed the included study in the '<a href="./references#CD004312-sec-0094" title="">Characteristics of included studies</a>' table. </p> <p>The included study enrolled a total of 66 adult participants, with a mean age of 50.65 years, 40 of whom were female (60%).It was performed in four centres in the Netherlands. The mean duration of cervical dystonia was 9.4 years. The overall disorder impairment at baseline was moderate, with a mean score of 15.9 on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS, <i>range 0 ‐ 85, higher is worse</i> ) disability subscale (<i>range 0 ‐ 30, higher is worse</i> ), and 14.7 on the Tsui scale (<i>range 1 ‐ 25, higher is worse</i>). The trial excluded people who had been previously exposed to Bt. All forms of idiopathic cervical dystonia were eligible, as long as they were not multifocal, generalised, or secondary. The number of dropouts was small (one in each arm (3%)). </p> <section id="CD004312-sec-0056"> <h5 class="title">Study design and interventions</h5> <p>The included trial had two arms. In the BtA arm, participants received intramuscular BtA at week zero and week eight, plus placebo tablets. In the trihexyphenidyl arm, participants received intramuscular placebo at week zero and week eight, and 2 mg trihexyphenidyl tablets. </p> <p>In both groups, tablets were taken daily, starting with half a tablet per day, and increasing by one‐half every three days, up to the maximum tolerated or maximum allowed dose (three tablets, four times a day). </p> <p>All injections were given with EMG guidance. The volume injected was left to the discretion of the investigator (mean BtA dose in the BtA arm: 292 U at week zero; 262 U at week eight). In one centre, five participants received half the planned BtA dose due to an error in dilution. </p> <p>The trial lasted for 12 weeks. Efficacy was evaluate using a modified intent‐to‐treat (ITT) analysis, which included all participants who received treatment. </p> </section> </section> <section id="CD004312-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We listed the excluded study, together with reasons for its exclusion, in the '<a href="./references#CD004312-sec-0095" title="">Characteristics of excluded studies</a>' table. </p> <p>We excluded one publication for being a duplicate (post‐hoc subgroup analysis of <a href="./references#CD004312-bbs2-0002" title="BransJW , AramidehM , KoelmanJHTM , LindeboomR , SpeelmanJD , Ongerboer de VisserBW . Electromyography before and after botulinum toxin versus trihexyphenidyl in cervical dystonia. Movement Disorders1998;13(Suppl 2):1. [DOI: 10.1212/wnl.51.3.815]BransJW , AramidehM , KoelmanJHTM , LindeboomR , SpeelmanJD , Ongerboer de VisserBW . Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl. Neurology1998;51(3):815-9. [DOI: 10.1212/wnl.51.3.815]">Brans 1998</a>). </p> </section> </section> <section id="CD004312-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD004312-sec-0094" title="">Characteristics of included studies</a>, 'Risk of bias' table. </p> <p>See <a href="#CD004312-fig-0002">Figure 2</a> for the 'Risk of bias' summary graphs. We based these assessments on the information available in the primary report data. </p> <div class="figure" id="CD004312-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD004312-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD004312-sec-0059"> <h4 class="title">Allocation</h4> <p>The process of random sequence generation was clearly described in the study (low risk), but the allocation concealment was not described (unclear risk). </p> </section> <section id="CD004312-sec-0060"> <h4 class="title">Blinding</h4> <p>We judged the blinding of participants and personnel involved in the trail to be at low risk, as the trial was double‐blind and double‐dummy, and the assessments were performed by a single independent and blinded investigator not involved in the treatment of the participants. However the higher frequency of adverse events in the trihexyphenidyl arm could have confounded the blinding and possibly contributed to performance bias. As so, we rated this item as unclear risk. </p> </section> <section id="CD004312-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>The reasons for missing data were summarised in the study report; we rated the study to be at low risk of bias for incomplete outcome data. </p> </section> <section id="CD004312-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We considered the study to be at low risk for reporting bias.</p> </section> <section id="CD004312-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <section id="CD004312-sec-0064"> <h5 class="title">Enriched population</h5> <p>Only Bt‐naive participants were eligible for the included trial, and the inclusion criteria do not seem to exclude less responsive forms of cervical dystonia. We rated this domain at low risk of bias. </p> </section> <section id="CD004312-sec-0065"> <h5 class="title">For‐profit bias</h5> <p>The study declared funding and supply of study interventions from industry sources, so we rated it at high risk of bias for funding and potential conflicts of interest. </p> </section> <section id="CD004312-sec-0066"> <h5 class="title">Publication bias</h5> <p>We intended to use funnel plots to explore publication bias. However, due to only one study being available, we did not conduct this analysis (<a href="./references#CD004312-bbs2-0072" title="SterneJAC , EggerM , MoherD , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbooks.">Sterne 2011</a>). </p> </section> </section> </section> <section id="CD004312-sec-0067"> <h3 class="title" id="CD004312-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD004312-tbl-0001"><b>Summary of findings 1</b> Botulinum toxin type A compared to anticholinergics for cervical dystonia</a> </p> <p>The key results of this review can be found in <a href="./full#CD004312-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD004312-sec-0068"> <h4 class="title">Preceding data analysis</h4> <p>See <a href="#CD004312-sec-0043">Dealing with missing data</a>. </p> <p>All results were extracted from the study report (<a href="./references#CD004312-bbs2-0001" title="BransJW , LindeboomR , SnoekJW , ZwartsMJ , vanWeerdenTW , BruntER , et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology1996;46(4):1066-72. ">Brans 1996</a>). </p> </section> <section id="CD004312-sec-0069"> <h4 class="title">Primary outcomes</h4> <section id="CD004312-sec-0070"> <h5 class="title">Cervical dystonia‐specific improvement</h5> <p>The included study assessed the primary outcome at week 12 following an injection session at week 0 and another at week 8.Tarsy 1997 </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004312-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004312-sec-0071"></div> <section id="CD004312-sec-0072"> <h3 class="title" id="CD004312-sec-0072">Summary of main results</h3> <p>This updated review included one randomised, parallel‐designed trial, that enrolled 66 people with cervical dystonia, none of whom had been previously treated with botulinum toxin (Bt) for their condition. </p> <p>As can be seen in the <a href="./full#CD004312-tbl-0001">summary of findings Table 1</a>, in comparison to trihexyphenidyl, the effect of botulinum toxin type A (BtA) for cervical dystonia remains very uncertain for cervical dystonia‐associated overall impairment, and associated pain, health‐related quality of life, tolerability, and adverse events. </p> <p>Treatment with trihexyphenidyl increased the risk of experiencing two specific adverse events: dry mouth and memory problems. No fatalities or serious adverse events were considered to be related to the BtA or trihexyphenidyl treatments in the trial. Data for special subpopulations, such as children or pregnant women, were not available. </p> <p>We found no information on subjective improvement, a dose‐response relationship with BtA, differences between BtA formulations or different anticholinergics, the utility of EMG‐guided injections, or the duration of treatment effect. </p> </section> <section id="CD004312-sec-0073"> <h3 class="title" id="CD004312-sec-0073">Overall completeness and applicability of evidence</h3> <p>The included trial addressed the primary research question directly, using validated assessment tools. However, it did not report data for all outcomes. This limited the amount of data available, and consequently, the confidence in overall conclusions. The number of adverse events was high in both the BtA and anticholinergic arms, as is common in movement disorders research, a large nocebo effect which may mask safety conclusions (<a href="./references#CD004312-bbs2-0020" title="DuarteGD , RodriguesFB , FerreiraJJ , CostaJ . Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?Parkinsonism &amp; Related Disorders2018;56:16-9. [DOI: 10.1016/j.parkreldis.2018.06.017]">Duarte 2018</a>; <a href="./references#CD004312-bbs2-0056" title="RatoML , DuarteGS , MestreT , deCarvalhoM , FerreiraJJ . Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology2018;17(10):842. [DOI: 10.1016/S1474-4422(18)30310-7]">Rato 2018</a>; <a href="./references#CD004312-bbs2-0057" title="RatoML , DuarteGS , FerreiraAN , AlvesM , MainoliB , TeodoroT , et al. Nocebo response in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism &amp; Related Disorders2019;65:13-9:13-9. [DOI: 10.1016/j.parkreldis.2019.04.015]">Rato 2019</a>; <a href="./references#CD004312-bbs2-0065" title="SilvaMA , DuarteGS , CamaraR , RodriguesFB , FernandesRM , AbreuD , et al. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology2017;88(23):2216-24. [DOI: 10.1212/WNL.0000000000004004]">Silva 2017</a>). </p> <p>The participants included in the trial were not fully representative of the overall population of people with cervical dystonia. By selecting Bt‐naive participants, we were unable to draw conclusions concerning all people with this condition. In clinical practice, clinicians may choose from more than one anticholinergic medication. Since the trial tested a single anticholinergic only, generalisation is limited. </p> <p>Finally, the sample size of the included trial was small, and many outcomes addressing clinically relevant questions were underpowered. More studies are needed to provide definitive evidence for these questions. </p> </section> <section id="CD004312-sec-0074"> <h3 class="title" id="CD004312-sec-0074">Quality of the evidence</h3> <p>See <a href="./references#CD004312-sec-0094" title="">Characteristics of included studies</a>, 'Risk of bias' tables, 'Risk of bias' summary tables (<a href="#CD004312-fig-0002">Figure 2</a>), and Summary of findings table 1. </p> <p><i>We considered the included trial to be at high risk for for‐profit bias, unclear risk of bias for allocation concealment and blinding of personnel and participants, and low risk of bias for the other domains. Results from all outcomes were below the optimal information size, and many crossed the line of no effect. This represented a major methodological limitation that may have resulted in a biased assessment of the intervention effect.</i> </p> <p>Taken together, there is very low certainty in the evidence that BtA improves cervical dystonia‐associated impairment, health‐related quality of life, and pain in cervical dystonia, more than trihexyphenidyl. There is very low certainty that tolerability is not different between BtA and trihexyphenidyl, based on the likelihood of participants dropping out of the trial. </p> </section> <section id="CD004312-sec-0075"> <h3 class="title" id="CD004312-sec-0075">Potential biases in the review process</h3> <p>Although we followed the methods recommended by Cochrane in order to minimise bias in the review process, certain areas do deserve attention. In particular, we did not search clinical trials registries, with the exception of the Cochrane clinical trial registry. Although this opens the current review to the potential bias of having missed trials, we consider this possibility highly unlikely, because we contacted other experts in this field, and USA and European trials in this area are well‐known. </p> <p>We were also unable to obtain data for all outcomes in the included trial, reducing the amount of data available for analysis. </p> </section> <section id="CD004312-sec-0076"> <h3 class="title" id="CD004312-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>Overall, the results of this updated review are in agreement with the conclusions of earlier versions (<a href="./references#CD004312-bbs2-0083" title="CostaJ , Espírito‐SantoCC , BorgesAA , MooreP , FerreiraJ , CoelhoMM , et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD004312. [DOI: 10.1002/14651858.CD004312.pub2]">Costa 2005</a>). They are also aligned with the current clinical practice guidelines of the American Academy of Neurology affirming that "BtA is probably more efficacious and better tolerated than trihexyphenidyl"(<a href="./references#CD004312-bbs2-0067" title="SimpsonDM , HallettM , AshmanEJ , ComellaCL , GreenMW , GronsethGS , et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology2016;10:1818-26.">Simpson 2016</a>) while the European Academy of Neurology reiterates that "No new class A or B [evidence/recommendations] are available for oral medications"(<a href="./references#CD004312-bbs2-0004" title="AlbaneseA , AsmusF , BhatiaKP , EliaAE , ElibolB , FilippiniG , et al. EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology2011;18:5-18.">Albanese 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004312-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/urn:x-wiley:14651858:media:CD004312:CD004312-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (2020 search)" data-id="CD004312-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_t/tCD004312-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (2020 search)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004312-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/urn:x-wiley:14651858:media:CD004312:CD004312-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD004312-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_t/tCD004312-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/media/CDSR/CD004312/image_n/nCD004312-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004312-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Botulinum toxin type A compared to anticholinergics for cervical dystonia</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p>Botulinum toxin type A<b>compared to anticholinergics for cervical dystonia</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cervical dystonia<br/><b>Setting:</b> any<br/><b>Intervention:</b> botulinum toxin type A (BtA)<br/><b>Comparison:</b> anticholinergics (trihexyphenidyl) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With anticholinergics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With BtA</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia‐specific improvement</b> </p> <p><i>assessed with TWSTRS disability subscale (0 to 33; higher = more disability)</i> </p> <p>follow‐up: 12 weeks<br/>№ of participants: 66 (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median cervical dystonia‐specific improvement with anticholinergics was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 points higher<br/>(0.68 higher to 4.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of BtA on cervical dystonia‐specific improvement compared with trihexyphenidyl. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p> <ul id="CD004312-list-0001"> <li> <p>Participants in the BtA arm reported 31 adverse events</p> </li> <li> <p>Participants in the trihexyphenidyl arm reported 76 adverse events.</p> </li> <li> <p>No serious adverse events was reported.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective evaluation of clinical status</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia‐specific pain</b> </p> <p><i>assessed with TWSTRS pain subcale (0 to 20; higher = more pain)</i> </p> <p>follow‐up: 12 weeks</p> <p>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>The study authors reported the mean improvement was 1 point in the trihexyphenidyl arm, and 3 points in the BtA arm. </p> <p>No measure of dispersion was given for this difference, and according to the authors it did not reach statistical significance. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p><i>assessed with MOS‐Quality of Life general health perception subscale (100‐points; higher = better)</i> </p> <p>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>The study authors reported the median change was ‐4 in the trihexyphenidyl arm, and +2 in the BtA arm). </p> <p>For the difference in medians, the authors only provide: 95% CI: 4 to 12, p‐value = 0.0023. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tolerability</b> </p> <p><i>assessed by dropouts due to adverse events</i><br/>follow‐up: 12 weeks<br/>№ of participants: 66<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.04 to 3.04) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain whether botulinum toxin type A results in less tolerability (more dropouts) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0%<br/>(0.4 to 27.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1% fewer<br/>(8.7 fewer to 18.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of effect</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>MD:</b> mean difference; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>TWSTRS</b>: Toronto Western Spasmodic Torticollis Rating Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to serious imprecision, as the optimal information size was not reached<br/><sup>b</sup>Downgraded one level due to study limitations; concerns with allocation procedures, blinding of participants and personnel, and for‐profit bias<br/><sup>c</sup>The total number of participants included was less than that required by sample size calculation, and the confidence interval included both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Botulinum toxin type A compared to anticholinergics for cervical dystonia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004312-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Botulinum toxin type A (BtA)‐non‐responsive</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People who do not experience the expected benefit from treatment with botulinum toxin type A </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cervical dystonia or spasmodic torticollis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chemodenervation</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse, and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dysphagia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discomfort or difficulty when swallowing.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dystonia</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A painful and disabling disorder, characterised by painful, involuntary posturing of the affected body region(s). </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Electromyography (EMG)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle. </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐naive</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People who have been treated in the past with botulinum toxin.</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Voluntary action</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Movements that people are able to control, start, and stop when they want to.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004312.pub3/full#CD004312-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004312.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004312-note-0022">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004312-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004312-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004312-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD004312-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004312-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004312\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004312\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004312\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004312\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004312\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004312.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004312.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004312.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004312.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004312.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725484653"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004312.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725484657"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004312.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7c5dbbbff4b8',t:'MTc0MDcyNTQ4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 